JP2005511683A - 新規なグルカゴンアンタゴニスト - Google Patents

新規なグルカゴンアンタゴニスト Download PDF

Info

Publication number
JP2005511683A
JP2005511683A JP2003549302A JP2003549302A JP2005511683A JP 2005511683 A JP2005511683 A JP 2005511683A JP 2003549302 A JP2003549302 A JP 2003549302A JP 2003549302 A JP2003549302 A JP 2003549302A JP 2005511683 A JP2005511683 A JP 2005511683A
Authority
JP
Japan
Prior art keywords
alkyl
compound
compound according
optionally
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003549302A
Other languages
English (en)
Japanese (ja)
Inventor
コドラ、ジャノス・ティボア
マドセン、ピーター
ラウ、ジェスパー
ジョルゲンセン、アンケル・スティーン
クリステンセン、インゲ・ソジャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2005511683A publication Critical patent/JP2005511683A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
JP2003549302A 2001-12-03 2002-11-28 新規なグルカゴンアンタゴニスト Withdrawn JP2005511683A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101789 2001-12-03
DKPA200201117 2002-07-18
PCT/DK2002/000800 WO2003048109A1 (fr) 2001-12-03 2002-11-28 Nouveaux antagonistes de glucagon

Publications (1)

Publication Number Publication Date
JP2005511683A true JP2005511683A (ja) 2005-04-28

Family

ID=26069105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003549302A Withdrawn JP2005511683A (ja) 2001-12-03 2002-11-28 新規なグルカゴンアンタゴニスト

Country Status (4)

Country Link
EP (1) EP1463715A1 (fr)
JP (1) JP2005511683A (fr)
AU (1) AU2002365622A1 (fr)
WO (1) WO2003048109A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502683A (ja) * 2004-06-14 2008-01-31 イーライ リリー アンド カンパニー グルカゴン受容体拮抗物質及びその調製並びに治療的使用
WO2009057784A1 (fr) * 2007-11-01 2009-05-07 Takeda Pharmaceutical Company Limited Composé hétérocyclique
WO2009110520A1 (fr) * 2008-03-05 2009-09-11 武田薬品工業株式会社 Composé hétérocyclique
WO2011027849A1 (fr) * 2009-09-04 2011-03-10 武田薬品工業株式会社 Composé hétérocyclique
JP2012500212A (ja) * 2008-08-13 2012-01-05 メタバシス・セラピューティクス・インコーポレイテッド グルカゴンアンタゴニスト
JP2013177426A (ja) * 2007-02-09 2013-09-09 Ligand Pharmaceuticals Inc グルカゴン受容体の新規アンタゴニスト
JP2014515370A (ja) * 2011-05-23 2014-06-30 ヤンセン ファーマシューティカ エヌ．ベー． グルカゴン受容体拮抗薬として有用なピコリンアミド−プロパン酸誘導体
JP2014520093A (ja) * 2011-05-23 2014-08-21 ヤンセン ファーマシューティカ エヌ．ベー． グルカゴン受容体拮抗薬として有用なビフェニル誘導体
JP2017538678A (ja) * 2014-11-05 2017-12-28 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 免疫調節剤
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
JP2020505413A (ja) * 2017-01-27 2020-02-20 ジェンフィＧｅｎｆｉｔ Ｒｏｒガンマモジュレーター及びその使用

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069158A2 (fr) 2003-01-27 2004-08-19 Merck & Co., Inc. Pyrazoles substitues, compositions contenant de tels composes et procedes d'utilisation
ES2428538T3 (es) * 2004-05-28 2013-11-08 Eli Lilly And Company Antagonistas del receptor de glucagón, preparación y usos terapéuticos
US7622491B2 (en) * 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
US8084489B2 (en) * 2005-02-11 2011-12-27 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
JP2008533200A (ja) 2005-03-21 2008-08-21 メルク エンド カムパニー インコーポレーテッド 置換アリールおよびヘテロアリール誘導体、かかる化合物を含有する組成物および使用法
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP1962820A2 (fr) * 2005-06-24 2008-09-03 DSMIP Assets B.V. Medicament pour le traitement du metabolisme de la glucose perturbee
WO2007015999A2 (fr) 2005-07-26 2007-02-08 Merck & Co., Inc. Procede de synthese d'un pyrazole substitue
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
PT1951661E (pt) 2005-11-17 2012-09-19 Lilly Co Eli Antagonistas do receptor de glucagon, preparação e utilizações terapêuticas
PT1951658E (pt) 2005-11-17 2012-11-12 Lilly Co Eli Antagonistas do receptor do glucagon, preparação e utilizações terapêuticas
ES2346246T3 (es) 2005-11-18 2010-10-13 ELI LILLY & COMPANY Antagonistas del receptor de glucagon, preparacion y usos terapeuticos.
US8691856B2 (en) 2005-11-22 2014-04-08 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
CA2629311C (fr) 2005-11-23 2014-05-06 Eli Lilly And Company Antagonistes de recepteur du glucagon, procedes de preparation et utilisations therapeutiques
EP2001472A2 (fr) 2006-03-23 2008-12-17 Merck and Co., Inc. Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
WO2007136577A2 (fr) 2006-05-16 2007-11-29 Merck & Co., Inc. Composés antagonistes du récepteur du glucagon, compositions contenant ces composés, et procédés d'utilisation
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2011520897A (ja) 2008-05-16 2011-07-21 シェーリング コーポレイション グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法
CN101768149B (zh) * 2008-12-30 2013-10-30 成都地奥制药集团有限公司 一类β-氨基酮(醇)衍生物及其用途
US20110281795A1 (en) 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
PE20100443A1 (es) * 2009-02-06 2010-06-25 Takeda Pharmaceutical Derivados del acido fenil-carbonil-amino-propanoico como antagonistas del glucagon
WO2012085745A1 (fr) 2010-12-23 2012-06-28 Pfizer Inc. Modulateurs du récepteur du glucagon
EA023517B1 (ru) 2011-02-08 2016-06-30 Пфайзер Инк. Модуляторы глюкагонового рецептора
CN103732578B (zh) 2011-07-22 2015-08-12 辉瑞大药厂 喹啉基胰高血糖素受体调节剂
US9725427B2 (en) 2012-03-16 2017-08-08 Biohaven Pharmaceutical Holding Company Limited Prodrugs of riluzole and their method of use
SI2968249T1 (sl) 2013-02-22 2019-04-30 Samumed, Llc Gama-diketoni kot aktivatorji signalne poti Wnt/beta-katenin
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN109071420B (zh) * 2016-06-14 2021-06-18 上海昂睿医药技术有限公司 酰胺类衍生物、其制备方法及其在医药上的用途
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬
CN110357813A (zh) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2004501897A (ja) * 2000-06-23 2004-01-22 ノボ　ノルディスク　アクティーゼルスカブ グルカゴン拮抗薬／逆作用薬

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502683A (ja) * 2004-06-14 2008-01-31 イーライ リリー アンド カンパニー グルカゴン受容体拮抗物質及びその調製並びに治療的使用
JP2013177426A (ja) * 2007-02-09 2013-09-09 Ligand Pharmaceuticals Inc グルカゴン受容体の新規アンタゴニスト
US10807946B2 (en) 2007-02-09 2020-10-20 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US10239829B2 (en) 2007-02-09 2019-03-26 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US9169201B2 (en) 2007-02-09 2015-10-27 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US9701626B2 (en) 2007-02-09 2017-07-11 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
JP2016041702A (ja) * 2007-02-09 2016-03-31 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体の新規アンタゴニスト
US8309580B2 (en) 2007-11-01 2012-11-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP5450083B2 (ja) * 2007-11-01 2014-03-26 武田薬品工業株式会社 複素環化合物
WO2009057784A1 (fr) * 2007-11-01 2009-05-07 Takeda Pharmaceutical Company Limited Composé hétérocyclique
WO2009110520A1 (fr) * 2008-03-05 2009-09-11 武田薬品工業株式会社 Composé hétérocyclique
JP5465658B2 (ja) * 2008-03-05 2014-04-09 武田薬品工業株式会社 複素環化合物
EA019752B1 (ru) * 2008-03-05 2014-06-30 Такеда Фармасьютикал Компани Лимитед Гетероциклическое амидное соединение и его применение для лечения/профилактики диабета
JP2015129133A (ja) * 2008-08-13 2015-07-16 メタバシス・セラピューティクス・インコーポレイテッドＭｅｔａｂａｓｉｓ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． グルカゴンアンタゴニスト
US10221130B2 (en) 2008-08-13 2019-03-05 Metabasis Therapeutics, Inc. Glucagon antagonists
JP2017101039A (ja) * 2008-08-13 2017-06-08 メタバシス・セラピューティクス・インコーポレイテッドＭｅｔａｂａｓｉｓ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． グルカゴンアンタゴニスト
US11352321B2 (en) 2008-08-13 2022-06-07 Metabasis Therapeutics, Inc. Glucagon antagonists
US9783494B2 (en) 2008-08-13 2017-10-10 Metabasis Therapeutics, Inc. Glucagon antagonists
JP2019112427A (ja) * 2008-08-13 2019-07-11 メタバシス・セラピューティクス・インコーポレイテッドＭｅｔａｂａｓｉｓ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． グルカゴンアンタゴニスト
JP2012500212A (ja) * 2008-08-13 2012-01-05 メタバシス・セラピューティクス・インコーポレイテッド グルカゴンアンタゴニスト
WO2011027849A1 (fr) * 2009-09-04 2011-03-10 武田薬品工業株式会社 Composé hétérocyclique
JP2014520093A (ja) * 2011-05-23 2014-08-21 ヤンセン ファーマシューティカ エヌ．ベー． グルカゴン受容体拮抗薬として有用なビフェニル誘導体
JP2014515370A (ja) * 2011-05-23 2014-06-30 ヤンセン ファーマシューティカ エヌ．ベー． グルカゴン受容体拮抗薬として有用なピコリンアミド−プロパン酸誘導体
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
JP2017538678A (ja) * 2014-11-05 2017-12-28 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 免疫調節剤
JP2020505413A (ja) * 2017-01-27 2020-02-20 ジェンフィＧｅｎｆｉｔ Ｒｏｒガンマモジュレーター及びその使用
JP7254703B2 (ja) 2017-01-27 2023-04-10 ジェンフィ Ｒｏｒガンマモジュレーター及びその使用

Also Published As

Publication number Publication date
EP1463715A1 (fr) 2004-10-06
WO2003048109A1 (fr) 2003-06-12
AU2002365622A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
JP2005511683A (ja) 新規なグルカゴンアンタゴニスト
US6762318B2 (en) Glucagon antagonists
US6881746B2 (en) Glucagon antagonists/inverse agonists
JP2006500325A (ja) 新規なグルカゴンアンタゴニスト
RU2374236C2 (ru) Амидные производные в качестве активаторов gk
US6953812B2 (en) Glucagon antagonists/inverse agonists
JP2005537231A (ja) 新規なグルカゴンアンタゴニスト
JP5140599B2 (ja) グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用
JP2004501897A (ja) グルカゴン拮抗薬／逆作用薬
WO2003053938A1 (fr) Nouveaux antagonistes/agonistes inverses du recepteur du glucagon
US6649641B2 (en) Glucagon antagonists/inverse agonists
WO2002040444A1 (fr) Antagonistes/agonistes inverses de glucagon
WO2004056763A2 (fr) Nouveaux antagonistes du glucagon
US20070015757A1 (en) Novel Glucagon Antagonists/Inverse Agonists
WO2003051357A1 (fr) Antagonistes/agonistes inverses du recepteur du glucagon
US20040152750A1 (en) Novel glucagon antagonists
EP1345891A1 (fr) Antagonistes/agonistes inverses du glucagon
US20040127560A1 (en) Glucagon antagonists/inverse agonists
US6821960B2 (en) Glucagon antagonists/inverse agonists
US20030212119A1 (en) Novel glucagon receptor antagonists/inverse agonists
TW200401634A (en) Novel glucagon antagonists
US20030229128A1 (en) Glucagon receptor antagonists/inverse agonists

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051110

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081219